Update on the use of pramipexole in the treatment of Parkinson’s disease

References

• AarslandDLarsenJPLimNGRange of neuropsychiatric disturbances in patients with Parkinson’s diseaseJ Neurol Neurosurg Psychiatry199967492610486397
   PubMed Web of Science ®Google Scholar
• AarslandDZaccaiJBrayneCA systematic review of prevalence studies of dementia in Parkinson’s diseaseMov Disord20052012556316041803
   PubMed Web of Science ®Google Scholar
• AdlerCHCavinessJNHentzJGRandomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s diseaseMov Disord2003182879312621632
   PubMed Web of Science ®Google Scholar
• AhlskogJEMuenterMDFrequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literatureMov Disord2001164485811391738
   PubMed Web of Science ®Google Scholar
• AhlskogJEMuenterMDMaraganoreDMFluctuating Parkinson’s disease. Treatment with the long-acting dopamine agonist cabergolineArch Neurol1994511236417986180
   PubMedGoogle Scholar
• AvornJSchneeweissSSudarskyLRSudden uncontrollable somnolence and medication use in Parkinson diseaseArch Neurol2005621242816087765
   PubMed Web of Science ®Google Scholar
• BennettJPJrPierceyMFPramipexole – a new dopamine agonist for the treatment of Parkinson’s diseaseJ Neurol Sci1999163253110223406
   PubMed Web of Science ®Google Scholar
• BentonAHHamsherKMultilingual aphasia examination manual1989Iowa City, IAUniversity of Iowa
   Google Scholar
• BiglanKMHollowayRGJrMcDermottMPRisk factors for somnolence, edema, and hallucinations in early Parkinson diseaseNeurology2007691879517620552
   PubMed Web of Science ®Google Scholar
• BouthenetMLSouilEMartresMPLocalization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNABrain Res1991564203191839781
   PubMed Web of Science ®Google Scholar
• BrooksDJAbbottRJLeesAJA placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson’s diseaseClin Neuropharmacol19982110179579296
   PubMed Web of Science ®Google Scholar
• BrusaLBassiAStefaniAPramipexole in comparison to l-dopa: a neuropsychological studyJ Neural Transm20031103738012658365
   PubMed Web of Science ®Google Scholar
• CarveyPMMcGuireSOLingZDNeuroprotective effects of D3 dopamine receptor agonistsParkinsonism Relat Disord2001721322311331189
   PubMed Web of Science ®Google Scholar
• CassarinoDSFallCPSmithTSPramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ionJ Neurochem1998712953019648878
   PubMed Web of Science ®Google Scholar
• ChaudhuriKRDhawanVBasuSValvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be sparedMov Disord2004191522315515009
   PubMed Web of Science ®Google Scholar
• ChenHZhangSMHernanMAWeight loss in Parkinson’s diseaseAnn Neurol200353676912731005
   PubMed Web of Science ®Google Scholar
• ConstantinescuRRomerMMcDermottMPImpact of pramipexole on the onset of levodopa-related dyskinesiasMov Disord2007221317917534955
   PubMed Web of Science ®Google Scholar
• CorriganMHDenahanAQWrightCEComparison of pramipexole, fluoxetine, and placebo in patients with major depressionDepress Anxiety200011586510812530
   PubMed Web of Science ®Google Scholar
• CotziasGCPapavasiliouPSTolosaEAporphines in Parkinson’s diseaseTrans Am Neurol Assoc1975100178811226602
   PubMedGoogle Scholar
• DeweyRB2ndReimoldSCO’SuilleabhainPECardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson diseaseArch Neurol2007643778017353380
   PubMed Web of Science ®Google Scholar
• DoddMLKlosKJBowerJHPathological gambling caused by drugs used to treat Parkinson diseaseArch Neurol20056213778116009751
   PubMed Web of Science ®Google Scholar
• DooneiefGMirabelloEBellKAn estimate of the incidence of depression in idiopathic Parkinson’s diseaseArch Neurol19924930571536634
   PubMedGoogle Scholar
• EtminanMGillSSamiiAComparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson’s disease: a meta-analysisDrug Saf2003264394412688834
   PubMed Web of Science ®Google Scholar
• EtminanMSamiiATakkoucheBIncreased risk of somnolence with the new dopamine agonists in patients with Parkinson’s disease: a meta-analysis of randomised controlled trialsDrug Saf200124863811665873
   PubMed Web of Science ®Google Scholar
• FantiniMLGagnonJFFilipiniDThe effects of pramipexole in REM sleep behavior disorderNeurology20036114182014638967
   PubMed Web of Science ®Google Scholar
• FruchtSRogersJDGreenePEFalling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropiniroleNeurology19995219081010371546
   PubMed Web of Science ®Google Scholar
• GoetzCGBlasucciLStebbinsGTSwitching dopamine agonists in advanced Parkinson’s disease: is rapid titration preferable to slow?Neurology1999521227910214748
   PubMed Web of Science ®Google Scholar
• GoldbergJFBurdickKEEndickCJPreliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depressionAm J Psychiatry2004161564614992985
   PubMed Web of Science ®Google Scholar
• GuMIravaniMMCooperJMPramipexole protects against apoptotic cell death by non-dopaminergic mechanismsJ Neurochem20049110758115569251
   PubMed Web of Science ®Google Scholar
• GuttmanMDouble-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. International Pramipexole-Bromocriptine Study GroupNeurology199749106059339690
   PubMed Web of Science ®Google Scholar
• GuttmanMJaskolkaJThe use of pramipexole in Parkinson’s disease: are its actions D(3) mediated?Parkinsonism Relat Disord20017231411331191
   PubMed Web of Science ®Google Scholar
• GuttmanMStewartDHusseyDInfluence of L-dopa and pramipexole on striatal dopamine transporter in early PDNeurology20015615596411402115
   PubMed Web of Science ®Google Scholar
• HallEDAndrusPKOostveenJANeuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neuronsBrain Res19967428089117424
   PubMed Web of Science ®Google Scholar
• HamiltonMA rating scale for depressionJ Neurol Neurosurg Psychiatry196023566214399272
   PubMed Web of Science ®Google Scholar
• HannaPARatkosLOndoWGSwitching from pergolide to pramipexole in patients with Parkinson’s diseaseJ Neural Transm2001108637011261747
   PubMed Web of Science ®Google Scholar
• HappeSBergerKThe association of dopamine agonists with daytime sleepiness, sleep problems and quality of life in patients with Parkinson’s disease – a prospective studyJ Neurol20012481062712013583
   PubMed Web of Science ®Google Scholar
• HauserRAGaugerLAndersonWMPramipexole-induced somnolence and episodes of daytime sleepMov Disord2000156586310928575
   PubMed Web of Science ®Google Scholar
• HauserRAMcDermottMPMessingSFactors associated with the development of motor fluctuations and dyskinesias in Parkinson diseaseArch Neurol20066317566017172616
   PubMed Web of Science ®Google Scholar
• HobsonDELangAEMartinWRExcessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders GroupJAMA20022874556311798367
   PubMed Web of Science ®Google Scholar
• HoehnMMYahrMDParkinsonism: onset, progression and mortalityNeurology196717427426067254
   PubMed Web of Science ®Google Scholar
• HollowayRGShoulsonIFahnSPramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trialArch Neurol20046110445315262734
   PubMed Web of Science ®Google Scholar
• HolmanAJMyersRRA randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medicationsArthritis Rheum200552249550516052595
   PubMed Web of Science ®Google Scholar
• HomannCNWenzelKSuppanKSleep attacks in patients taking dopamine agonists: reviewBMJ20023241483712077032
   PubMed Web of Science ®Google Scholar
• HäselbarthVFJustus-ObenauerHPeilHPharmacokinectics and bioavailability of pramipexole: Comparison of plasma levels after intravenous and oral administration in healthy volunteers (M/2730/0029)Upjohn Technical Report1994a 7215–94–016
   Google Scholar
• HäselbarthVKLohmannJJustus-ObenauerHPharmacokinetics and metabolism of [14c]pramipexole after single intravenous and oral doses in healthy volunteers (Protocol M/2730/0030)Upjohn Technical Report1994b 7215–94–014
   Google Scholar
• InzelbergRCarassoRLSchechtmanEA comparison of dopamine agonists and catechol-O-methyltransferase inhibitors in Parkinson’s diseaseClin Neuropharmacol200023262611154093
   PubMed Web of Science ®Google Scholar
• InzelbergRSchechtmanENisipeanuPCabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson’s disease: an evidence-based comparisonDrugs Aging2003208475512964891
   PubMed Web of Science ®Google Scholar
• IzumiYSawadaHYamamotoNNovel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicityEur J Pharmacol20075571324017161393
   PubMed Web of Science ®Google Scholar
• JohnsMWA new method for measuring daytime sleepiness: the Epworth sleepiness scaleSleep19911454051798888
   PubMed Web of Science ®Google Scholar
• JoyceJNWoolseyCRyooHLow dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson’s disease, and downregulates the dopamine transporter via the D3 receptorBMC Biol200422215473914
   PubMed Web of Science ®Google Scholar
• JunghannsSFuhrmannJTSimonisGValvular heart disease in Parkinson’s disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography studyMov Disord200722234817094087
   PubMed Web of Science ®Google Scholar
• KarlsenKHTandbergEArslandDHealth related quality of life in Parkinson’s disease: a prospective longitudinal studyJ Neurol Neurosurg Psychiatry200069584911032608
   PubMed Web of Science ®Google Scholar
• KartzinelRTeychennePGillespieMMBromocriptine and levodopa (with or without carbidopa) in parkinsonismLancet19762272559850
   PubMed Web of Science ®Google Scholar
• Kleiner-FismanGFismanDNRisk factors for the development of pedal edema in patients using pramipexoleArch Neurol200764820417420306
   PubMed Web of Science ®Google Scholar
• KlosKJBowerJHJosephsKAPathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson’s disease and multiple system atrophyParkinsonism Relat Disord200511381616109498
   PubMed Web of Science ®Google Scholar
• KompolitiKAdlerCHRamanRGender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamicsNeurology20025814182212011296
   PubMed Web of Science ®Google Scholar
• KumruHSantamariaJValldeoriolaFIncrease in body weight after pramipexole treatment in Parkinson’s diseaseMov Disord2006211972416972276
   PubMed Web of Science ®Google Scholar
• LangAFMunsatTLAssessment of Parkinson’s diseaseQuantification of Neurologic Deficit1989Boston, MassButterworth-Heinemann285309
   Google Scholar
• LattanziLDell’OssoLCassanoPPramipexole in treatment-resistant depression: a 16-week naturalistic studyBipolar Disord200243071412479663
   PubMed Web of Science ®Google Scholar
• LeWDJankovicJXieWAntioxidant property of pramipexole independent of dopamine receptor activation in neuroprotectionJ Neural Transm200010711657311129106
   PubMed Web of Science ®Google Scholar
• LemkeMRBrechtHMKoesterJAnhedonia, depression, and motor functioning in Parkinson’s disease during treatment with pramipexoleJ Neuropsychiatry Clin Neurosci2005172142015939976
   PubMed Web of Science ®Google Scholar
• LemkeMRBrechtHMKoesterJEffects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson’s diseaseJ Neurol Sci20062482667016814808
   PubMed Web of Science ®Google Scholar
• LibmanIGawelMJRiopelleRJA comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of “de novo” Parkinson’s disease patientsCan J Neurol Sci198714576803319120
   PubMed Web of Science ®Google Scholar
• LiebermanARanhoskyAKortsDClinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group studyNeurology19974916289222185
   PubMed Web of Science ®Google Scholar
• LorefaltBGranerusAKUnossonMAvoidance of solid food in weight losing older patients with Parkinson’s diseaseJ Clin Nurs20061514041217038101
   PubMed Web of Science ®Google Scholar
• LuCBharmalASuchowerskyOGambling and Parkinson diseaseArch Neurol20066329816476827
   PubMedGoogle Scholar
• MamikonyanESiderowfADDudaJELong-term follow-up of impulse control disorders in Parkinson’s diseaseMov Disord200823758017960796
   PubMed Web of Science ®Google Scholar
• MierauJPramipexole: A dopamine-receptor agonist for treatment of Parkinson’s DiseaseClin Neuropharmacol199518Suppl 1S195S206
   Google Scholar
• MierauJSchingnitzGBiochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonistEur J Pharmacol1992215161701356788
   PubMed Web of Science ®Google Scholar
• MierauJSchneiderFJEnsingerHAPramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptorsEur J Pharmacol199529029367664822
   PubMed Web of Science ®Google Scholar
• MizunoYYanagisawaNKunoSRandomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson’s diseaseMov Disord20031811495614534919
   PubMed Web of Science ®Google Scholar
• MollerJCOertelWHKosterJLong-term efficacy and safety of pramipexole in advanced Parkinson’s disease: results from a European multicenter trialMov Disord2005206021015726540
   PubMed Web of Science ®Google Scholar
• MontgomerySAAsbergMA new depression scale designed to be sensitive to changeBr J Psychiatry19791343829444788
   PubMed Web of Science ®Google Scholar
• MontplaisirJNicolasADenesleRRestless legs syndrome improved by pramipexole: a double-blind randomized trialNeurology1999529384310102409
   PubMed Web of Science ®Google Scholar
• NavanPFindleyLJJeffsJADouble-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson’s diseaseMov Disord2003a181768012539211
   PubMed Web of Science ®Google Scholar
• NavanPFindleyLJJeffsJARandomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremorMov Disord2003b1813243114639675
   PubMed Web of Science ®Google Scholar
• NievesAVLangAETreatment of excessive daytime sleepiness in patients with Parkinson’s disease with modafinilClin Neuropharmacol200225111411981239
   PubMed Web of Science ®Google Scholar
• NoyesKDickAWHollowayRGPramipexole v. levodopa as initial treatment for Parkinson’s disease: a randomized clinical-economic trialMed Decis Making2004244728515358996
   PubMed Web of Science ®Google Scholar
• NoyesKDickAWHollowayRGPramipexole and levodopa in early Parkinson’s disease: dynamic changes in cost effectivenessPharmacoeconomics20052312577016336019
   PubMed Web of Science ®Google Scholar
• NoyesKDickAWHollowayRGPramipexole versus levodopa in patients with early Parkinson’s disease: effect on generic and disease-specific quality of lifeValue Health20069283816441522
   PubMed Web of Science ®Google Scholar
• O’SuilleabhainPEDeweyRBJrContributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson diseaseArch Neurol200259986912056935
   PubMed Web of Science ®Google Scholar
• OndoWGFayleRAtassiFModafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trialJ Neurol Neurosurg Psychiatry2005761636916291885
   PubMed Web of Science ®Google Scholar
• PanTXieWJankovicJBiological effects of pramipexole on dopaminergic neuron-associated genes: relevance to neuroprotectionNeurosci Lett2005377106915740846
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupSafety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study GroupJAMA1997278125309214527
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupPramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study GroupJAMA20002841931811035889
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupDopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progressionJAMA200228716536111926889
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupPramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritageClin Neuropharmacol200730728517414939
   PubMed Web of Science ®Google Scholar
• PausSBrechtHMKosterJSleep attacks, daytime sleepiness, and dopamine agonists in Parkinson’s diseaseMov Disord2003186596712784269
   PubMed Web of Science ®Google Scholar
• PeraltaCWolfEAlberHValvular heart disease in Parkinson’s disease vs. controls: An echocardiographic studyMov Disord20062111091316622856
   PubMed Web of Science ®Google Scholar
• PinterMMPogarellOOertelWHEfficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre studyJ Neurol Neurosurg Psychiatry1999664364110201413
   PubMed Web of Science ®Google Scholar
• PinterMMRutgersAWHebenstreitEAn open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson’s diseaseJ Neural Transm200010713072311145006
   PubMed Web of Science ®Google Scholar
• PizzagalliDAEvinsAESchetterECSingle dose of a dopamine agonist impairs reinforcement learning in humans: Behavioral evidence from a laboratory-based measure of reward responsivenessPsychopharmacology, (Berl)20081962213217909750
   PubMed Web of Science ®Google Scholar
• PluckGCBrownRGApathy in Parkinson’s diseaseJ Neurol Neurosurg Psychiatry2002736364212438462
   PubMed Web of Science ®Google Scholar
• PoeweWHoglBAkathisia, restless legs and periodic limb movements in sleep in Parkinson’s diseaseNeurology200463S12615505135
   PubMed Web of Science ®Google Scholar
• PoeweWWenningGKApomorphine: an underutilized therapy for Parkinson’s diseaseMov Disord2000157899411009181
   PubMed Web of Science ®Google Scholar
• PoeweWHRascolOQuinnNEfficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trialLancet Neurol200765132017509486
   PubMed Web of Science ®Google Scholar
• PogarellOGasserTvan HiltenJJPramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre studyJ Neurol Neurosurg Psychiatry2002727132012023411
   PubMed Web of Science ®Google Scholar
• PresgravesSPBorwegeSMillanMJInvolvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cellsExp Neurol20041901577015473989
   PubMed Web of Science ®Google Scholar
• QuickfallJSuchowerskyOPathological gambling associated with dopamine agonist use in restless legs syndromeParkinsonism Relat Disord200713535617270485
   PubMed Web of Science ®Google Scholar
• RavinaBEidelbergDAhlskogJEAlbinRLBrooksDJCarbonMThe role of radiotracer imaging in Parkinson diseaseNeurology2005642081515668415
   PubMed Web of Science ®Google Scholar
• RazmyALangAEShapiroCMPredictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonistsArch Neurol2004619710214732626
   PubMed Web of Science ®Google Scholar
• ReichmannHBrechtMHKosterJPramipexole in routine clinical practice: a prospective observational trial in Parkinson’s diseaseCNS Drugs2003179657314533946
   PubMed Web of Science ®Google Scholar
• ReichmannHOdinPBrechtHMChanging dopamine agonist treatment in Parkinson’s disease: experiences with switching to pramipexoleJ Neural Transm Suppl2006172517447411
   PubMedGoogle Scholar
• ReitanRTrail making testManual for administration and scoring1992South TusconReitan Neuropsychology Laboratory
   Google Scholar
• RektorovaIRektorIBaresMPramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized studyEur J Neurol20031039940612823492
   PubMed Web of Science ®Google Scholar
• RektorovaIRektorIBaresMCognitive performance in people with Parkinson’s disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapyEur J Neurol20051291515613141
   PubMed Web of Science ®Google Scholar
• ReljaMKlepacNA dopamine agonist, pramipexole, and cognitive functions in Parkinson’s diseaseJ Neurol Sci2006248251416797593
   PubMed Web of Science ®Google Scholar
• RinneUKBraccoFChouzaCCabergoline in the treatment of early Parkinson’s disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study GroupNeurology19974836389040722
   PubMed Web of Science ®Google Scholar
• RomigiABrusaLMarcianiMGSleep episodes and daytime somnolence as result of individual susceptibility to different dopaminergic drugs in a PD patient: a polysomnographic studyJ Neurol Sci200522871015607203
   PubMed Web of Science ®Google Scholar
• RothmanRBBaumannMHSavageJEEvidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medicationsCirculation200010228364111104741
   PubMed Web of Science ®Google Scholar
• SayeedIParvezSWinkler-StuckKPatch clamp reveals powerful blockade of the mitochondrial permeability transition pore by the D2-receptor agonist pramipexoleFASEB J200620556816407457
   PubMed Web of Science ®Google Scholar
• SchadeRAndersohnFSuissaSDopamine agonists and the risk of cardiac-valve regurgitationN Engl J Med2007356293817202453
   PubMed Web of Science ®Google Scholar
• SchifittoGFOakesDShulmanLMR Fatigue in levodopa-naïve subjects with early Parkinson’s disease, abstract at the First World Parkinson Congress2006Washington DC, USA
   Google Scholar
• SchmidtMHKoshalVBSchmidtHSUse of pramipexole in REM sleep behavior disorder: results from a case seriesSleep Med200674182316815751
   PubMed Web of Science ®Google Scholar
• SchragAJahanshahiMQuinnNWhat contributes to quality of life in patients with Parkinson’s disease?J Neurol Neurosurg Psychiatry2000693081210945804
   PubMed Web of Science ®Google Scholar
• ScoyniRMAielloLTraniIDrug adverse events and drop-out risk: a clinical caseArch Gerontol Geriatr200744Suppl 13596417317475
   PubMed Web of Science ®Google Scholar
• ShannonKMBennettJPJrFriedmanJHEfficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study GroupNeurology19974972489305331
   PubMed Web of Science ®Google Scholar
• ShulmanLMMinagarARabinsteinAThe use of dopamine agonists in very elderly patients with Parkinson’s diseaseMov Disord200015664810928576
   PubMed Web of Science ®Google Scholar
• SnaithRPHamiltonMMorleySA scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure ScaleBr J Psychiatry1995167991037551619
   PubMed Web of Science ®Google Scholar
• StarksteinSEMaybergHSPreziosiTJReliability, validity, and clinical correlates of apathy in Parkinson’s diseaseJ Neuropsychiatry Clin Neurosci1992413491627973
   PubMed Web of Science ®Google Scholar
• SvenssonKCarlssonAHuffRMBehavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptorsEur J Pharmacol1994263235437843260
   PubMed Web of Science ®Google Scholar
• TanEKOndoWClinical characteristics of pramipexole-induced peripheral edemaArch Neurol2000577293210815140
   PubMed Web of Science ®Google Scholar
• TandbergELarsenJPAarslandDThe occurrence of depression in Parkinson’s disease. A community-based studyArch Neurol19965317598639068
   PubMed Web of Science ®Google Scholar
• TandbergELarsenJPKarlsenKA community-based study of sleep disorders in patients with Parkinson’s diseaseMov Disord19981389599827612
   PubMed Web of Science ®Google Scholar
• TothMJFishmanPSPoehlmanETFree-living daily energy expenditure in patients with Parkinson’s diseaseNeurology19974888919008499
   PubMed Web of Science ®Google Scholar
• UbertiDBianchiIOlivariLPramipexole prevents neurotoxicity induced by oligomers of beta-amyloidEur J Pharmacol2007569194617572405
   PubMed Web of Science ®Google Scholar
• WeinerWJFactorSAJankovicJThe long-term safety and efficacy of pramipexole in advanced Parkinson’s diseaseParkinsonism Relat Disord200171152011248592
   PubMed Web of Science ®Google Scholar
• WeintraubDMoralesKHMobergPJAntidepressant studies in Parkinson’s disease: a review and meta-analysisMov Disord2005201161915954137
   PubMed Web of Science ®Google Scholar
• WeintraubDSiderowfADPotenzaMNAssociation of dopamine agonist use with impulse control disorders in Parkinson diseaseArch Neurol2006639697316831966
   PubMed Web of Science ®Google Scholar
• WongKSLuCSShanDEEfficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson’s diseaseJ Neurol Sci200321681714607306
   PubMed Web of Science ®Google Scholar
• WrightCESissonTLIchhpuraniAKSteady-state pharmacokinetic properties of pramipexole in healthy volunteersJ Clin Pharmacol19973752059208359
   PubMed Web of Science ®Google Scholar
• WynaldaMAWienkersLCAssessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screenDrug Metab Dispos199725121149321526
   PubMed Web of Science ®Google Scholar
• YamamotoMUesugiTNakayamaTDopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control studyNeurology2006671225917030757
   PubMed Web of Science ®Google Scholar
• ZanettiniRAntoniniAGattoGValvular heart disease and the use of dopamine agonists for Parkinson’s diseaseN Engl J Med2007356394617202454
   PubMed Web of Science ®Google Scholar
• ZouLJankovicJRoweDBNeuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicityLife Sci19996412758510227583
   PubMed Web of Science ®Google Scholar
• ZungWWA Self-Rating Depression ScaleArch Gen Psychiatry196512637014221692
   PubMed Web of Science ®Google Scholar